Direct acting antiviral therapy after liver transplantation

Current Opinion in Gastroenterology

Volumn 32, Issue 3, 2016, Pages 152-158

  Kwo, Paul Y ^a  

^a INDIANA UNIVERSITY HEALTH   (United States)

Author keywords

Direct acting antiviral agents; Fibrosing cholestatic hepatitis C; Hepatitis C; Orthotopic liver transplant

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; DASABUVIR; LEDIPASVIR; OMBITASVIR; PARITAPREVIR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR;

ANTIVIRAL THERAPY; CHOLESTATIC HEPATITIS; DIRECT ACTING ANTIVIRAL THERAPY; HEPATITIS C; HUMAN; LIVER GRAFT; LIVER TRANSPLANTATION; REVIEW; TREATMENT RESPONSE; COMPLICATION; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS; VIROLOGY;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION;

EID: 84961886745     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000266     Document Type: Review

References (20)

1. O'Leary JG, Randall H, Onaca N, et al. Postliver transplant survival in hepatitis C patients is improving over time. Liver Transpl 2009; 15:360-368.
2. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142:1264-1273.
3. Adam R, Karam V, Delvart V, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol 2012; 57:675-688.
4. Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122:889-896.
5. Crippin JS, McCashland T, Terrault N, et al. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transplantation 2002; 8:350-355.
6. Coilly A, Roche B, Dumortier J, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol 2014; 60:78-86.
7. Kwo PY, Ghabril M, Lacerda MA, et al. Telaprevir with peginterferon/ribavirin for retreatment of null responders with advanced fibrosis postorthotopic liver transplant. Clin Transplant 2014; 28:722-727.
8. Charlton M. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents-a potentially lethal cocktail. Hepatology 2011; 54:3-5.
9. Dick TB, Lindberg LS, Ramirez DD, Charlton MR. A clinician's guide to drugdrug interactions with direct acting antiviral agents for the treatment of hepatitis C virus infection. Hepatology 2015; 63:634-643.
10. Gordon FD, Kwo P, Ghalib R, et al. Peginterferon-alpha-2b and ribavirin for hepatitis C recurrence postorthotopic liver transplantation. J Clin Gastroenterol 2012; 46:700-708.
11. Forns X, Charlton M, Denning J, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology 2015; 61:1485-1494.
12. Charlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015; 148:108-117.
13. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015; 149:649-659.
14. Manns M, Forns X, Samuel D, et al. G02: ledipasvir/sofosbuvir with ribavirin is safe and efficacious in decompensated and post liver transplantation patients with HCV infection: preliminary results of the prospective solar 2 trial. J Hepatol 2015; 62:S187-S188.
15. Poordad F, Schiff E, Vierling J, et al. LO8: Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: phase 3 ALLY-1 study. J Hepatol 2015; 62:S261-S262.
16. Coilly A, Fougerou C, De Ledinghen V, et al. G15: the association of sofosbuvir and daclatasvir for treating severe recurrence of HCV infection after liver transplantation: results from a large French prospective multicentric ANRS CO23 CUPILT cohort. J Hepatol 2015; 62:S236-S237.
17. Brown RS, O'Leary JG, Reddy KR, et al. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network. Liver Transplant 2016; 22:24-33.
18. Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014; 371:2375-2382. High-sustained response rates can be achieved with paritaprevir/ombitasvir/dasabuvir/ribavirin for 24 weeks.
19. Leroy V, Dumortier J, Coilly A, et al. Efficacy of sofosbuvir and daclatasvir in patients with fibrosing cholestatic hepatitis C after liver transplantation. Clin Gastroenterol Hepatol 2015; 13:1993-2001.
20. Forns X, Mutimer D, Manns M, et al. P0779: Ledipasvir/sofosbuvir with ribavirin for the treatment of fibrosing cholestatic hepatitis C after liver transplantation. J Hepatol 2015; 62:S623.